Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know

The latest trading session saw Eli Lilly (LLY) ending at $778.62, denoting a -0.05% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.39%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, lost 0.32%.Coming into today, shares of the drugmaker had gained 7.12% in the past month. In that same time, the Medical sector lost 0.78%, while the S&P 500 gained 3.6%.The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company's upcoming EPS is projected at $5.49, signifying a 120.48% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $14.08 billion, up 50.57% from the prior-year quarter.For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.17 per share and a revenue of $45.59 billion, representing changes of +108.39% and +33.62%, respectively, from the prior year.It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.23% downward. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 59.16. This denotes a premium relative to the industry's average Forward P/E of 13.9.Investors should also note that LLY has a PEG ratio of 2.96 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.46 as of yesterday's close.The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 38% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks